The era of precision medicine: A clinical case for ALK+ non small cell lung cancer and review of therapeutic options

Abstract

In the last 2 decades the therapeutic approach in advanced and metastatic non small cell lung cancer (NSCLC) was changed, that marked the era of precision medicine in oncology. Today, the use of tyrosine kinase inhibitors (TKIs) based on molecular genetic characteristics is standard in the treatment of NSCLC. The discovery of rearrangements in the EML4-ALK gene in a limited population of patients with NSCLC has given us new innovative treatment approaches with better survival results to achieve an optimal therapeutic strategy.